To confirm that mesenchymal genes are transcriptionally induced upon EZH2i treatment we exposed MCF-7 cells to another highly specific inhibitor of EZH2 that is approved for cancer treatment by the US Food and Drug Administration (EPZ-6438, tazemetostat) [21], and measure its impact on gene expression by mRNA-seq. Here, EZH2 is linked to cancer.